Viewing Study NCT03796052



Ignite Creation Date: 2024-05-06 @ 12:33 PM
Last Modification Date: 2024-10-26 @ 1:01 PM
Study NCT ID: NCT03796052
Status: COMPLETED
Last Update Posted: 2020-11-04
First Post: 2019-01-04

Brief Title: Study Determining Safety and Efficacy of Avena Sativa Oat Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
Sponsor: Johnson Johnson Consumer Inc JJCI
Organization: Johnson Johnson Consumer and Personal Products Worldwide

Study Overview

Official Title: A Single Center Clinical Study to Determine the Safety and Efficacy of an Avena Sativa Skincare Regimen for Therapy-Related Pruritus and Xerosis in Cancer Patients
Status: COMPLETED
Status Verified Date: 2020-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study will test the safety and efficacy of three topical agents containing oat kernel flour to determine how well they relieve skin dryness and itching related to cancer therapies Participants will receive a body wash a body cream and an anti-itch balm to use at home for 4-6 weeks
Detailed Description: Many patients undergoing cancer therapies experience skin reactions like dry skin rash redness itchiness and hyperpigmentation Dry skin and itching are especially common for those undergoing chemotherapy and targeted treatments

Skincare products containing Avena sativa oat kernel flour have a long history of tolerance and efficacy in treating various skin conditions involving pruritus itching and xerosis dry skin as Avena sativa oat kernel flour is known for its skin protectant properties and soothing effects on skin This study will evaluate the safety and efficacy of a regimen of three topical agents containing Avena sativa oat kernel flour for cancer patients experiencing mild to moderate pruritus andor xerosis

Participants will received the products at Baseline Visit 1 and return to the clinical site at Week 5 - 1 week for Visit 2 In addition questionnaires will be completed remotely between Baseline and Visit 2

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None